Master Relative Effectiveness Assessment - Training Course Brussels

The course will cover key concepts and provide an overview of methods used in the assessment and appraisal of pharmaceuticals during the pricing and reimbursement (funding) decision-making process.

  • Key principles, notions and stakeholders in pricing & reimbursement policy
  • Role of health technology assessment (HTA) in pricing & reimbursement policy
  • Main approaches to HTA Europe
  • HTA in different EU countries
  • Relative effectiveness assessment as a basis for reimbursement decision
  • Similarities and differences between regulatory and HTA requirements in the assessment process

Targeted audience
The course is aimed at professionals with limited/no technical experience of HTA who may face market access challenges and opportunities on a daily basis. The course will be of interest to participants from the pharmaceuticalindustry working in the field of:
  • Market Access
  • Government and Public Affairs
  • Health Economics & Outcome Research
  • Patient Advocacy
  • Drug Development
  • Regulatory Affairs
  • Marketing
  • Medical Affairs

As the training will cover perspectives from different stakeholders, representatives from government agencies, payer organisations, health insurance companies as well as hospital managers, patient advocates, academia and non-profit organisations are encouraged to attend as well.